2018 Ventricular Tachycardia Drug Development Pipeline Analysis Report- Companies, Drugs, Clinical Trials, Latest Developments in Ventricular Tachycardia Market
Ventricular tachycardia is a type of arrhythmia, which starts in ventricles. The heart’s electric system causes rapid heartbeat, leading to ventricular fibrillation that can cause sudden cardiac death. The rapid heartbeat causes inadequate time to refill prior to pumping blood. This lowers the supply of blood to the body, which causes dizziness, faintness and even cardiac arrest. It is often treated through medications or heart surgery.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Ventricular Tachycardia pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Ventricular Tachycardia pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Ventricular Tachycardia pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
To assist researchers, investors and business development managers, VPA Research has come up with a comprehensive report on Ventricular Tachycardia pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Ventricular Tachycardia pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Ventricular Tachycardia pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 VENTRICULAR TACHYCARDIA PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Ventricular Tachycardia Pipeline Snapshot
2.3 Ventricular Tachycardia Pipeline by Phase
2.4 Ventricular Tachycardia Pipeline by Company
2.5 Ventricular Tachycardia Pipeline by Mechanism of Action
3 VENTRICULAR TACHYCARDIA- COMPANY WISE PIPELINE ANALYSIS
Audentes Therapeutics, Inc.
Espero Biopharma, Inc
Gilead Sciences, Inc.
Ono Pharmaceutical Co., Ltd.
Elex Biotech LLC
ARMGO Pharma, Inc.
4 VENTRICULAR TACHYCARDIA R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN VENTRICULAR TACHYCARDIA PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
1.1 List of LIST OF FIGURES
1.2 List of Tables
2 VENTRICULAR TACHYCARDIA PIPELINE ANALYSIS
2.1 Disease and Pipeline Overview
2.2 Ventricular Tachycardia Pipeline Snapshot
2.3 Ventricular Tachycardia Pipeline by Phase
2.4 Ventricular Tachycardia Pipeline by Company
2.5 Ventricular Tachycardia Pipeline by Mechanism of Action
3 VENTRICULAR TACHYCARDIA- COMPANY WISE PIPELINE ANALYSIS
Audentes Therapeutics, Inc.
Espero Biopharma, Inc
Gilead Sciences, Inc.
Ono Pharmaceutical Co., Ltd.
Elex Biotech LLC
ARMGO Pharma, Inc.
4 VENTRICULAR TACHYCARDIA R&D PIPELINE SNAPSHOTS
Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/ License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details
5 RECENT DEVELOPMENTS IN VENTRICULAR TACHYCARDIA PIPELINE
6 APPENDIX
6.1 About VPA Research
6.2 Sources and Research Methodology
LIST OF FIGURES
Figure 1: Ventricular Tachycardia Pipeline by Phase, H2- 2018
Figure 2: Ventricular Tachycardia Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Ventricular Tachycardia Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
Figure 1: Ventricular Tachycardia Pipeline by Phase, H2- 2018
Figure 2: Ventricular Tachycardia Pipeline by Companies, H2- 2018
Figure 3: Company Wise Pipeline Drug Phases, H2- 2018
Figure 4: Ventricular Tachycardia Pipeline by Mechanism of Action, H2- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H2- 2018
LIST OF TABLES
Ventricular Tachycardia Pipeline by Phase, H2- 2018
Ventricular Tachycardia Pipeline by Companies, H2- 2018
Ventricular Tachycardia Pipeline by Mechanism of Action, H2- 2018
Table 1: Audentes Therapeutics, Inc. Ventricular Tachycardia Pipeline Drugs, H2- 2018
Table 2: Espero Biopharma, Inc Ventricular Tachycardia Pipeline Drugs, H2- 2018
Table 3: Gilead Sciences, Inc. Ventricular Tachycardia Pipeline Drugs, H2- 2018
Table 4: Ono Pharmaceutical Co., Ltd. Ventricular Tachycardia Pipeline Drugs, H2- 2018
Table 5: Elex Biotech LLC Ventricular Tachycardia Pipeline Drugs, H2- 2018
Table 6: ARMGO Pharma, Inc. Ventricular Tachycardia Pipeline Drugs, H2- 2018
Ventricular Tachycardia Pipeline by Phase, H2- 2018
Ventricular Tachycardia Pipeline by Companies, H2- 2018
Ventricular Tachycardia Pipeline by Mechanism of Action, H2- 2018
Table 1: Audentes Therapeutics, Inc. Ventricular Tachycardia Pipeline Drugs, H2- 2018
Table 2: Espero Biopharma, Inc Ventricular Tachycardia Pipeline Drugs, H2- 2018
Table 3: Gilead Sciences, Inc. Ventricular Tachycardia Pipeline Drugs, H2- 2018
Table 4: Ono Pharmaceutical Co., Ltd. Ventricular Tachycardia Pipeline Drugs, H2- 2018
Table 5: Elex Biotech LLC Ventricular Tachycardia Pipeline Drugs, H2- 2018
Table 6: ARMGO Pharma, Inc. Ventricular Tachycardia Pipeline Drugs, H2- 2018
